RAF1 and cancer: Because the affinity between Ras and the Raf-CRD alone is relatively weak, the disruption of its interactions with Ras, either through the interswitch region involving loop 3 or through loop 8, holds strong potential as a novel approach for targeting Ras- and Raf-related cancers.